ramiyo.bsky.social
@ramiyo.bsky.social
Cancer Immunotherapy Researcher
Reposted
From 2010 to 2016 (latest data I have ), NIH research contributed to EVERY drug approved by the FDA
March 22, 2025 at 10:44 AM
Reposted
STAND UP FOR SCIENCE SPEAKER ANNOUNCEMENT! ☀️

Dr. Francis Collins will be speaking at Stand Up for Science in D.C. on March 7th!

More speaker announcements coming soon, stay tuned! 👀☀️
March 6, 2025 at 12:00 AM
Reposted
Welcome to the Bluesky account for Stand Up for Science 2025!

Keep an eye on this space for updates, event information, and ways to get involved. We can't wait to see everyone #standupforscience2025 on March 7th, both in DC and locations nationwide!

#scienceforall #sciencenotsilence
February 12, 2025 at 5:04 PM
Reposted
Cool preprint by ⁦Dustin and coworkers on how various T cell engager formats, w/varying geometries/rigidities, impact synapse structure and potency

www.biorxiv.org/content/10.1...
Solution structure and synaptic analyses reveal determinants of bispecific T cell engager potency
Bispecific T-cell engagers (TcEs) link T cell receptors to tumor-associated antigens on cancer cells, forming cytotoxic immunological synapses (IS). Close membrane-to-membrane contact (≤13 nm) has bee...
www.biorxiv.org
November 27, 2024 at 5:47 PM
Reposted
ICYMI - over the summer Maria Parkhurst from our branch published one of the first reports of clinical responses after adoptive cell transfer of TCR engineered private neoantigen (tumor mutation) targeting T cells in metastatic cancer patients 🧪🦠🔬🩺 1/3 #Immunosky
www.nature.com/articles/s41...
Adoptive transfer of personalized neoantigen-reactive TCR-transduced T cells in metastatic colorectal cancer: phase 2 trial interim results - Nature Medicine
Preliminary findings in seven patients with mismatch repair-proficient metastatic colorectal cancer who were treated in the context of a phase 2 trial show that adoptive transfer of autologous periphe...
www.nature.com
November 24, 2024 at 5:02 PM